Nearly all of those 28 devices were cleared after just two studies, and overall, three or fewer studies were conducted for nearly half of the devices, according to a paper published in the Journal of the American Medical Association.
“Medical device regulation in the U.S. is well-known to be more rigorous than in other parts of the world,” senior author Joseph S. Ross, MD, senior author of the study, told Reuters Health, but said there had not been a comprehensive review of the evidence behind high-risk devices. “The difference is, in many European countries they have much better capacity to follow devices once they are in practice,” Dr. Ross told Reuters Health. “They allow devices on the market quicker in the U.K., but follow the devices so they can observe them in practice.”
In addition, five of the devices had no post-market studies conducted to evaluate them and ten were later recalled. Half of the studies did not compare the high-risk devices to preexisting ones.
More articles on clinical quality:
FDA releases new guidance for cleaning ‘unsafe’ scopes
10 of the most interesting infection control developments this year
Music in the OR: Soothing or a safety hazard?
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
